- Home
- PSO vs LEGN Comparison
PSO vs LEGN Comparison
Compare PSO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSO
- LEGN
- Stock Information
- Founded
- PSO 1844
- LEGN 2014
- Country
- PSO United Kingdom
- LEGN United States
- Employees
- PSO N/A
- LEGN N/A
- Industry
- PSO Books
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- PSO Consumer Discretionary
- LEGN Health Care
- Exchange
- PSO Nasdaq
- LEGN Nasdaq
- Market Cap
- PSO 9.0B
- LEGN 9.1B
- IPO Year
- PSO 2000
- LEGN 2020
- Fundamental
- Price
- PSO $13.60
- LEGN $43.09
- Analyst Decision
- PSO
- LEGN Strong Buy
- Analyst Count
- PSO 0
- LEGN 13
- Target Price
- PSO N/A
- LEGN $81.46
- AVG Volume (30 Days)
- PSO 283.9K
- LEGN 1.1M
- Earning Date
- PSO 01-01-0001
- LEGN 11-18-2024
- Dividend Yield
- PSO 2.17%
- LEGN N/A
- EPS Growth
- PSO 23.43
- LEGN N/A
- EPS
- PSO 0.63
- LEGN N/A
- Revenue
- PSO $4,485,194,688.00
- LEGN $455,991,000.00
- Revenue This Year
- PSO N/A
- LEGN $108.95
- Revenue Next Year
- PSO $3.99
- LEGN $81.26
- P/E Ratio
- PSO $20.47
- LEGN N/A
- Revenue Growth
- PSO N/A
- LEGN 176.93
- 52 Week Low
- PSO $10.84
- LEGN $38.60
- 52 Week High
- PSO $14.20
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- PSO 54.49
- LEGN 33.84
- Support Level
- PSO $13.29
- LEGN $47.63
- Resistance Level
- PSO $13.56
- LEGN $51.77
- Average True Range (ATR)
- PSO 0.11
- LEGN 2.60
- MACD
- PSO 0.01
- LEGN -0.31
- Stochastic Oscillator
- PSO 90.00
- LEGN 5.14
About PSO Pearson Plc
U.K.-listed Pearson is the world's largest educational provider. The company has been disposing of noncore businesses such as the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider. While Pearson's primary activity centres on higher-level education, the firm also has significant operations in providing clinical assessments, professional certification and testing.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.